ABIVAX: management transactions · France · AMF

About ABIVAX

Abivax SA is a French clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases. Founded in Paris in 2013, the company has gradually established itself as a visible European biotech player by building its strategy around immune-regulatory mechanisms inspired by the body’s natural biology. Abivax has been listed on Euronext Paris since June 26, 2015 and has also traded on the Nasdaq Global Market since October 2023, giving it exposure to both European and U.S. capital markets. Its ISIN is FR0012333284. The company’s business is centered on the development of its lead asset, obefazimod, an orally administered modulator of microRNA-124 (miR-124). This candidate is primarily being advanced in ulcerative colitis, a chronic inflammatory bowel disease, with the goal of offering a differentiated therapeutic option for patients who remain inadequately controlled by existing treatments. Abivax positions obefazimod as the cornerstone of its pipeline, with phase 3 clinical data readouts representing key value-creation catalysts. The company has also highlighted a proprietary chemical library that may provide additional long-term development opportunities. Historically, Abivax initially built its scientific platform around immunology and antiviral approaches, before sharpening its focus on chronic inflammatory diseases. This strategic shift reflects management’s intent to concentrate resources on programs with the highest clinical and commercial potential. Today, Abivax remains primarily a research and development company, with its economic model depending on clinical progress, possible strategic partnerships, and, ultimately, commercialization of approved products. Abivax has an international footprint, with activities and teams in France and the United States to support clinical trials, investor relations, and regulatory development. Its profile was further strengthened by inclusion in the Nasdaq Biotechnology Index in December 2025, underscoring growing recognition within the global biotech ecosystem. As a growth-stage biotechnology issuer, Abivax combines advanced science, significant clinical risk, and substantial upside potential if its lead program successfully reaches the market.